Spindle checkpoint protein hMad2 and histone H3 phosphoserine 10 mitosis marker in pediatric solid tumors

Anticancer Research

Volumn 26, Issue 6 C, 2006, Pages 4687-4694

  Idikio, Halliday A ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

H3 histone phosphoserine 10; hMad2; Mitosis marker; Pediatric tumors; Spindle checkpoint

Indexed keywords

BIOLOGICAL MARKER; HISTONE H3; PHOSPHOSERINE; PROTEIN MAD2;

ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; HEPATOBLASTOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOMA; MITOSIS; NEPHROBLASTOMA; NEUROBLASTOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SARCOMA; SCORING SYSTEM; SOLID TUMOR; SPINDLE CELL; STAINING; TREATMENT RESPONSE;

CALCIUM-BINDING PROTEINS; CELL CYCLE PROTEINS; CHILD; HEPATOBLASTOMA; HISTONES; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA; MITOSIS; NEOPLASMS; NEUROBLASTOMA; PHOSPHORYLATION; PHOSPHOSERINE; REPRESSOR PROTEINS; SARCOMA; WILMS TUMOR;

EID: 33845952458     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Shah J and Cleveland DW: Waiting for anaphase: Mad2 and the spindle assembly checkpoint. Cell 103: 997-1000, 2000.
2. Shapiro G and Harper J: Anticancer drug targets: cell cycle and checkpoint control. J Clin Invest 104: 1645-1653, 1999.
3. Fang G: Checkpoint protein Bub1 acts synergistically with Mad2 to inhibit anaphase-promoting complex. Mol Biol Cell 13: 755-766, 2002.
4. Cleveland D, Mao Y and Sullivan K: Centromere and kinetochores: from epigenetics to mitotic checkpoint signaling. Cell 112: 407-21, 2003.
5. Zhou J, Yao J and Joshi H: Attachment and tension in the spindle assembly checkpoint. J Cell Science 115: 3547-3555, 2002.
6. Kops GJ, Foltz DR and Cleveland DW: Lethality to human cancer cells through massive chromosome loss by inhibition of the mitotic checkpoint. Proc Natl Acad Sci 101(23): 8699-8704, 2004.
7. Bharadwaj R and Yu H: The spindle checkpoint, aneuploidy, and cancer. Oncogene 23(11): 2016-2027, 2004.
8. Michel L, Benezra R, Diaz-Rodriguez E: MAD2 dependent mitotic checkpoint defects in tumorigenesis and tumor cell death: a double edged sword. Cell Cycle 3(8): 990-992, 2004.
9. Burds A, Lutum A and Sorger P: Generating chromosome instability through the simultaneous deletion of mad2 and p53. Proc Natl Acad Sci 102: 11296-11301, 2005.
10. Ditchfield C, Johnson V, Tighe A et al: Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores. J Cell Biol 161: 267-280, 2003.
11. Skoufias D, Andreassen P, Lacroix F, Wilson L and Margolis R: Mammalian mad2 and bub1/bubR1 recognize distinct spindle-attachment and kinetochore -tension checkpoints. Proc Natl Acad Sci 98: 4492-4497, 2001.
12. Hanks S and Rahman N: Aneuploidy-cancer predisposition syndromes: A new link between the mitotic spindle checkpoint and cancer. Cell Cycle 4(2): 225-227, 2005.
13. Doncic A, Ben-Jacob E, Barkai N: Evaluating putative mechanisms of the mitotic spindle checkpoint. Proc Natl Acad Sci 102: 6332-6337, 2005.
14. Li GQ and Zhang HF: Mad2 and p27 expression profiles in colorectal cancer and its clinical significance. World J Gastroenterol 10(21): 3218-32120, 2004.
15. Hernando E, Nahle Z, Juan G et al: Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. Nature 430(7001): 797-802, 2004.
16. Kops GJ, Kim Y, Weaver BA et al: ZW10 links mitotic checkpoint signaling to the structural kinetochore. J Cell Biol 169(1): 49-60, 2005.
17. Kops G, Weaver B and Cleveland D: On the road to cancer: Aneuploidy and the mitotic checkpoint. Nat Rev Cancer 5: 773-785, 2005.
18. Shichiri M, Yoshinaga K, Hisatomi H, Sugihara K and Hirata Y: Genetic and epigenetic inactivation of mitotic checkpoint Genes hbub1 and hbubr1 and Their Relationship to Survival. Cancer Res 62: 13-17, 2002.
19. Attiyeh E, London W, Mosse Y et al: Chromosome 1p and 11q Deletions and Outcome in Neuroblastoma. New Eng J Med 353(24): 2243-2253, 2005.
20. Brodeur G: Neuroblastoma biological insights into a clinical enigma. Nat Rev Cancer 3: 203-216, 2003.
21. Bode A and Dong Z: Inducible covalent posttranslational modification of histone H3. Sci STKE: e4, 2005.
22. Prigent C and Dimitrov S: Phosphorylation of serine 10 in histone H3, what for? J Cell Science 116: 3677-3685, 2003.
23. Hirota T, Lipp J, Ban-Hock T and Jan-Micheal P: Histone H3 serine 10 phosphorylation by aurora B causes HP1 dissociation from heterochromatin. Nature 438: 1176-1180, 2005.
24. Lim J-H, Catez F, Birger Y et al: Chromosomal protein HMGN1 modulates histone H3 phosphorylation. Mol Cell 15: 573-584, 2004.
25. Michel L, Diaz-Rodriguez E, Narayan G, Hernando E, Murty V and Benezra R: Complete loss of the tumor suppressor mad2 causes premature cyclin B degradation and mitotic failure in human somatic cells. Proc Natl Acad Sci 101: 4459-4464, 2004.
26. D'Angiolela V, Mari C, Nocera D, Rametti L and Grieco D: The spindle checkpoint requires cyclin-dependent kinase activity. Genes & Dev 17: 2520-2525, 2003.
27. Yoon D-S, Wersto R, Zhou W et al: Variable levels of chromosome instability and mitotic spindle checkpoint defects in breast cancer. Am J Pathol 161: 391-397, 2002.
28. Masuda A, Maeno K, Nakagawa T, Saito H and Takahashi T: Association between mitotic spindle checkpoint impairment and susceptibility to the induction of apoptosis by anti-microtubule agents in human lung cancers. Am J Pathol 163: 1109-1116, 2003.
29. Cheung HW, Jin DY, Ling MT et al: Mitotic arrest deficient 2 expression induces chemosensitization to a DNA-damaging agent, cisplatin, in nasopharyngeal carcinoma cells. Cancer Res 65(4): 1450-1458, 2005.
30. Hernando E, Orlow I, Nohales G, Benazra R and Cordon-Cardo C: Molecular analyses of the mitotic checkpoint components hsMad2, hBUB1 and hBUB3 in human cancer. Int J Cancer 95: 223-227, 2001.
31. Wassmann K, Liberal V and Benezra R: Mad2 phosphorylation regulates its association with Mad1 and the APC/C. EMBO 22: 797-806, 2003.
32. Weaver B and Cleveland D: Decoding the links between mitosis, cancer, and chemotherapy: The mitotic checkpoint, adaptation, and cell death. Cancer Cell 8: 7-12, 2005.
33. Erenpreisa J and Cragg M: Mitotic death: a mechanism of survival? A review. Cancer Cell Int 1: 1, 2001.
34. Nitta M, Kobayashi O, Honda S, Hirota T, Kuninaka S, Marumoto T, Ushio Y and Saya H: Spindle checkpoint function is required for mitotic catastrophe induced by DNA damaging agents. Oncogene 23(39): 6548-6558, 2004.
35. Sudo T, Nitta M, Saya H and Ueno NT: Dependence of paclitaxel sensitivity on a functional spindle assembly checkpoint. Cancer Res 64(7): 2502-2508, 2004.
36. Shah M and Schwartz G: Cell cycle-mediated Drug Resistance: An emerging concept in cancer therapy. Clin Cancer Res 7(8): 2168-2181, 2001.
37. Jordan M and Wilson L: Microtubules as a target for anticancer drugs. Nat Rev Cancer 4(4): 253-263, 2004.
38. Vogel C, Kienitz A, Muller R and Bastians H: The mitotic spindle checkpoint is a critical determinant for topoisomerase-based chemotherapy. J Biol Chem 211(280): 4025-4028, 2005.
39. Kasai T, Iwanaga Y, Iha H and Jeang K-T: Prevalent loss of mitotic spindle checkpoint in adult T-cell leukemia confers resistance to microtubule inhibitors. J Biol Chem 277: 5187-5193, 2002.
40. Wu C-W, Chi C-W and Huang T-S: Elevated levels of spindle checkprotein MAD2 correlates with cellular mitotic arrest, but not with aneuploidy and clinicopathological characteristics in gastric cancer. World J Gastroenterol 10(22): 3240-3244, 2004.
41. Wang X, Jin D, Wong H, Feng H, Wong Y and Tsao S: MAD2-induced sensitization to vincristine is associated with mitotic arrest and Raf/Bcl-2 phosphorylation in nasopharyngeal carcinoma cells. Oncogene 22(9): 109-116, 2003.
42. Ohira M, Oba S, Nakamura Y et al: Expression profiling using a tumor-specific cDNA microarray predicts the prognosis of intermediate risk neuroblastoma. Cancer Cell 7(4): 337-350, 2005.
43. Wei J, Greer B, Westermann F et al: Prediction of clinical outcome using gene expression profiling and artificial neural networks for patients with neuroblastoma. Cancer Res 64: 6883-6891, 2004.
44. Luttikhuis M, Powell J, Rees S et al: Neuroblastomas with chromosome 11q loss and single copy MYCN comprise a biologically distinct group of tumors with adverse prognosis. Brit J Cancer 85(4): 531-537, 2001.
45. McArdle L, McDermott M, Purcell R et al: Oligonucleotide microarray analysis of gene expression in neuroblastoma displaying loss of chromosome 11q. Carcinogenesis 25(9): 1599-1609, 2004.
46. Valsesia-Wittmann S, Magdeleine M, Dupasquier S et al: Oncogenic cooperation between H-Twist and N-Myc overrides failsafe programs in cancer cells. Cancer Cell 6: 625-630, 2005.
47. Alaminos M, Davalos V, Cheung N-K and Gerald W: Clustering of gene hypermethylation associated with clinical risk groups in neuroblstoma. J Natl Cancer Inst 96(16): 1208-1219, 2004.
48. Re D, Thomas R, Behringer K and Diehl V: From Hodgkin disease to Hodgkin lymphoma: biologic insights and therapeutic potential. Blood 105: 4553-4560, 2005.
49. Linardic C, Downie D, Qualman S, Bentley R and Counter C: Gentic modeling of human rhabdomyosarcomas. Cancer Res 65: 4490-4495, 2005.
50. Keller C, Arenkiel B, Coffin C, El-Bardesy N, DePinho R and Capecchi M: Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: cooperativity of Ink4a/ARF and TP53 loss of function. Genes & Dev 18: 2614-2626, 2004.
51. Man T, Lu X, Jaeweon K et al: Genome-wide array comparative genomic hybridization analysis reveals distinct amplifications in osteosarcoma. BMC Cancer 4(1): 45, 2004.
52. Hu-Lieskovan S, Zhang J, Wu L, Shimada H, Schofield D and Triche T: EWS-FL1 fusion protein up-regulates critical genes in neural crest development and is responsible for the observed phenotype of Ewings family of tumors. Cancer Res 65: 4633-4644, 2005.
53. Weber R, Pietsch T, von Schweintz D and Lichter P: Characterization of genomic alterations in hepatoblstomas A role for gains on chromosomes 8q and 20 as predictors of poor outcome. Am J Pathol 157: 571-578, 2000.
54. Hachem A and Gartenhaus R: Oncogenes as molecular targets in lymphoma. Blood 106(75): 1911-1923, 2005.
55. Scotting P, Walker D and Perilongo G: Childhood solid tumors: a development disorder. Nat Rev Cancer 5: 481-487, 2005.
56. Tao W, South V, Zhang Y et al: Induction of apoptosis by an inhibitor of the mitotic kinesin KSP requires both activation of the spindle assembly checkpoint and mitotic slippage. Cancer Cell 8(7): 49-59, 2005.